Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus Camrelizumab in Advanced ESCC
NCT04984018Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04984018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984018.